Ototoxicity Clinical Trials

4 recruiting

Ototoxicity Trials at a Glance

8 actively recruiting trials for ototoxicity are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Baltimore, Charleston, and Denver. Lead sponsors running ototoxicity studies include Johns Hopkins University, Institut de Cancérologie de Lorraine, and Direction Centrale du Service de Santé des Armées.

Browse ototoxicity trials by phase

Treatments under study

About Ototoxicity Clinical Trials

Looking for clinical trials for Ototoxicity? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ototoxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ototoxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Ototoxicity, Drug-Induced
Kevin Winthrop105 enrolled5 locationsNCT05730283
Recruiting
Phase 2

Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial

Sensorineural Hearing LossOtotoxicityOtotoxicity, Drug-Induced+1 more
Siriraj Hospital40 enrolled1 locationNCT07364747
Recruiting
Not Applicable

Vestibular Implantation in Older Adults

Sensation DisordersVestibular DiseasesOther Disorders of Vestibular Function, Bilateral+4 more
Johns Hopkins University15 enrolled1 locationNCT05676944
Recruiting
Not Applicable

Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction

Sensation DisordersVestibular DiseasesOther Disorders of Vestibular Function, Bilateral+4 more
Johns Hopkins University8 enrolled1 locationNCT05674786
Recruiting
Not Applicable

Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted.

CancerQuality of LifeHearing Disorders+1 more
Institut de Cancérologie de Lorraine52 enrolled1 locationNCT05936034
Recruiting

Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma

OtotoxicityVestibular Schwannoma
University Hospital, Geneva258 enrolled1 locationNCT05641441
Recruiting
Phase 2

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

NephrotoxicityMucositisOtotoxicity
Matrix Biomed, Inc.120 enrolled9 locationsNCT03480971
Recruiting

Diagnostic of Various Ototoxicity Induced by Cancer Treatment

Ototoxicity, Drug-Induced
Direction Centrale du Service de Santé des Armées540 enrolled1 locationNCT06490029